摘要
【目的】探讨氨溴索注射液在小儿支原体肺炎治疗中的临床效果。【方法】回顾性分析本院收治的96例小儿支原体肺炎患者的临床资料，根据治疗方法不同分为观察组和对照组，每组各48例，对照组患者给予阿奇霉素注射液治疗，观察组患者在对照组的基础上加用氨溴索注射液治疗，疗程结束后，比较两组患者的临床疗效、症状改善情况以及不良反应发生情况。【结果】观察组的总有效率高达93．75％（45／48），对照组的总有效率为81．25％（39／48），两组相比较差异具有显著性（P〈0．05）；观察组患者的退热时间、咳嗽消失时间、肺哆音消失时间以及住院时间均显著短于对照组患者（P〈0．05）；观察组的总不良反应发生率为8．33％，明显低于对照组（16．67％），两组相比较差异具有显著性（P〈0．05）。【结论】氨溴索注射液治疗小儿支原体肺炎可在短时间内消除发热、咳嗽、肺哆音等临床症状，效果显著且安全性高。
[Objective] To investigate the clinical efficacy of ambroxol injection for the treatment of chil- dren with mycoplasma pneumonia. [Methods] Clinical data of 96 pediatric patients with mycoplasma pneumonia in our hospital were analyzed retrospectively. According to different treatment methods, all patients were di- vided into treatment group and control group with 48 cases in each group. The control group was treated with azithromycin injection, while the treatment group was treated with ambroxol injection on the basis of the treat- ment of control group. After treatment, the clinical efficacy, the improvement of symptoms and adverse events were compared between two groups. [Results] The total effective rate of control group was up to 93.75% （45/ 48）, and that of control group was 81.25% （39/48）, and there were significant differences between the two groups（ P d0.05）. The fever clearance time, cough disappearance time, pulmonary rales disappearance time and hospital stay in the treatment group were significantly shorter than those in the control group（ P 〈0.05）. The total incidence of adverse reactions in the treatment group was 8.33%, and that in the control group was 16.67%, and there were significant differences between two groups（ P 〈0.05）. [Conclusion] Ambroxol in- jection for the treatment of mycoplasma pneumonia can eliminate fever, cough, pulmonary rales and other symptoms in a short time, and has significant efficacy and high safety.
出处
《医学临床研究》
CAS
2013年第8期1492-1494,共3页
Journal of Clinical Research
